Article
Cost minimization analysis of short-duration antiviral prophylaxis for hepatitis C positive donor kidney transplants.
Journal of the American Pharmacists Association : JAPhA - 1 Jan 2000
Jay Jessica S, Patterson Julie A, Zhang Yiran, Ijioma Stephen C, Carroll Norman V, Holdford David A, Sterling Richard K, Gupta Gaurav, Yakubu Idris
Abstract excerpt
BACKGROUND: Trials describing 4-12 week courses of direct-acting antiviral drugs (DAAs) to treat hepatitis C virus (HCV) transmission from infected donors to uninfected kidney transplant recipients (D+/R-transplants), may be limited in application by costs and delayed access to expensive DAAs. A short prophylactic strategy may be safer and cost-effective. Here, we report a cost minimization analysis using the...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.